Cet anticorps Humanized Monoclonal détecte spécifiquement Trop2 (Sacituzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7795133
Aperçu rapide pour Recombinant Trop2 (Sacituzumab Biosimilar) anticorps (ABIN7795133)
Antigène
Trop2 (Sacituzumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp Trop2 (Sacituzumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg
Attributs du produit
What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
niveau d'endotoxine
Less than 0.5 EU/mg of protein as determined by LAL method